MX2013014577A - Compuestos de heteroarilo como ligandos del receptor 5-ht4. - Google Patents
Compuestos de heteroarilo como ligandos del receptor 5-ht4.Info
- Publication number
- MX2013014577A MX2013014577A MX2013014577A MX2013014577A MX2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A MX 2013014577 A MX2013014577 A MX 2013014577A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor ligands
- heteroaryl compounds
- compounds
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Semiconductor Integrated Circuits (AREA)
- Structures Or Materials For Encapsulating Or Coating Semiconductor Devices Or Solid State Devices (AREA)
Abstract
La presente invención se relaciona con compuestos novedosos de fórmula (I) y sus sales farmacéuticamente aceptables, y con composiciones que los contienen. (Ver Formula) La presente invención también se relaciona con un proceso para la preparación de los compuestos novedosos mencionados y de sus sales farmacéuticamente aceptables. Los compuestos de fórmula (I) son útiles en el tratamiento de diversos trastornos relacionados con los receptores 5-HT4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3203CH2011 | 2011-09-19 | ||
| PCT/IN2012/000011 WO2013042135A1 (en) | 2011-09-19 | 2012-01-05 | Heteroaryl compounds as 5-ht4 receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013014577A true MX2013014577A (es) | 2014-03-31 |
| MX337721B MX337721B (es) | 2016-03-16 |
Family
ID=46001349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013014577A MX337721B (es) | 2011-09-19 | 2012-01-05 | Compuestos de heteroarilo como ligandos del receptor 5-ht4. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9079894B2 (es) |
| EP (1) | EP2758394B1 (es) |
| JP (1) | JP5714729B2 (es) |
| KR (1) | KR101551481B1 (es) |
| CN (1) | CN103380131B (es) |
| AP (1) | AP3307A (es) |
| AU (1) | AU2012311057B2 (es) |
| BR (1) | BR112014001083B8 (es) |
| CA (1) | CA2823548C (es) |
| CY (1) | CY1116173T1 (es) |
| DK (1) | DK2758394T3 (es) |
| EA (1) | EA022374B1 (es) |
| ES (1) | ES2531885T3 (es) |
| HR (1) | HRP20150229T1 (es) |
| IL (1) | IL231305A0 (es) |
| ME (1) | ME02107B (es) |
| MX (1) | MX337721B (es) |
| PL (1) | PL2758394T3 (es) |
| PT (1) | PT2758394E (es) |
| RS (1) | RS53940B1 (es) |
| SG (1) | SG2014003560A (es) |
| SI (1) | SI2758394T1 (es) |
| SM (1) | SMT201500087B (es) |
| WO (1) | WO2013042135A1 (es) |
| ZA (1) | ZA201309100B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012169649A1 (en) * | 2011-06-07 | 2012-12-13 | Dainippon Sumitomo Pharma Co., Ltd. | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof |
| US20160039796A1 (en) * | 2013-04-05 | 2016-02-11 | Abc Bioscience As | Barettin and derivatives thereof for medical use, in particular for the treatment of diseases related to oxidative stress or inflammation, and for preserving or washing organs |
| AU2014369085B2 (en) | 2013-12-16 | 2017-02-23 | Suven Life Sciences Limited | Indazole compounds as 5-HT4 receptor agonists |
| CN106604921B (zh) * | 2014-08-16 | 2019-04-02 | 苏文生命科学有限公司 | 大规模生产1-异丙基-3-{5-[1-(3-甲氧基丙基)哌啶-4-基]-[1，3，4]噁二唑-2-基}-1h-吲唑草酸盐的方法 |
| DK3265459T3 (da) | 2015-02-13 | 2019-07-15 | Suven Life Sciences Ltd | Amidforbindelser som 5-ht4-receptoragonister |
| CN107540568A (zh) * | 2017-08-25 | 2018-01-05 | 许昌恒生制药有限公司 | 一种乙氧酰胺苯甲酯的制备方法 |
| KR20230155613A (ko) * | 2018-10-18 | 2023-11-10 | 수벤 라이프 사이언시스 리미티드 | 5-ht4 수용체 작용제의 새로운 용도 |
| AU2020282759A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| CN110746450A (zh) * | 2019-09-17 | 2020-02-04 | 济南康和医药科技有限公司 | 一种贝前列素钠关键中间体的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0596933A1 (en) * | 1991-08-03 | 1994-05-18 | Smithkline Beecham Plc | 5-ht4 receptor antagonists |
| TW360653B (en) * | 1995-03-01 | 1999-06-11 | Janssen Pharmaceutica Nv | A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition |
| CA2236357C (en) | 1995-11-09 | 2006-10-17 | Synthelabo | 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one derivatives for use as 5-ht4 or h3 receptor ligands |
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| DK1689742T3 (da) | 2003-11-24 | 2010-05-17 | Pfizer | Quinoloncarboxylsyreforbindelser med 5-HT-receptor-agonistisk aktivitet |
| ES2366375T3 (es) * | 2005-02-22 | 2011-10-19 | Pfizer, Inc. | Derivados de oxiindol, como agonistas del receptor 5-ht4. |
| ES2523459T3 (es) | 2005-02-25 | 2014-11-26 | Raqualia Pharma Inc | Derivados de benzisoxazol |
| ATE449092T1 (de) | 2005-07-22 | 2009-12-15 | Pfizer | Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors |
| WO2007071598A1 (en) * | 2005-12-23 | 2007-06-28 | F. Hoffmann-La Roche Ag | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US20080255203A1 (en) * | 2007-04-12 | 2008-10-16 | Abbott Laboratories | Heterocyclic compounds and their methods of use |
| US8524751B2 (en) * | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
-
2012
- 2012-01-05 KR KR1020137020582A patent/KR101551481B1/ko active Active
- 2012-01-05 SG SG2014003560A patent/SG2014003560A/en unknown
- 2012-01-05 WO PCT/IN2012/000011 patent/WO2013042135A1/en not_active Ceased
- 2012-01-05 CN CN201280009072.1A patent/CN103380131B/zh active Active
- 2012-01-05 ES ES12716662.7T patent/ES2531885T3/es active Active
- 2012-01-05 SI SI201230163T patent/SI2758394T1/sl unknown
- 2012-01-05 AU AU2012311057A patent/AU2012311057B2/en active Active
- 2012-01-05 EP EP12716662.7A patent/EP2758394B1/en active Active
- 2012-01-05 BR BR112014001083A patent/BR112014001083B8/pt not_active IP Right Cessation
- 2012-01-05 DK DK12716662.7T patent/DK2758394T3/en active
- 2012-01-05 ME MEP-2015-47A patent/ME02107B/me unknown
- 2012-01-05 JP JP2013554062A patent/JP5714729B2/ja active Active
- 2012-01-05 RS RS20150234A patent/RS53940B1/sr unknown
- 2012-01-05 EA EA201391056A patent/EA022374B1/ru unknown
- 2012-01-05 US US13/982,486 patent/US9079894B2/en active Active
- 2012-01-05 PT PT127166627T patent/PT2758394E/pt unknown
- 2012-01-05 PL PL12716662T patent/PL2758394T3/pl unknown
- 2012-01-05 CA CA2823548A patent/CA2823548C/en active Active
- 2012-01-05 HR HRP20150229AT patent/HRP20150229T1/hr unknown
- 2012-01-05 AP AP2013007301A patent/AP3307A/xx active
- 2012-01-05 MX MX2013014577A patent/MX337721B/es active IP Right Grant
-
2013
- 2013-12-04 ZA ZA2013/09100A patent/ZA201309100B/en unknown
-
2014
- 2014-03-04 IL IL231305A patent/IL231305A0/en active IP Right Grant
-
2015
- 2015-03-30 CY CY20151100308T patent/CY1116173T1/el unknown
- 2015-04-09 SM SM201500087T patent/SMT201500087B/xx unknown
- 2015-06-10 US US14/735,237 patent/US9636335B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013014577A (es) | Compuestos de heteroarilo como ligandos del receptor 5-ht4. | |
| MX351305B (es) | Antagonistas del receptor de mineralocorticoides. | |
| PH12013501557A1 (en) | Glucagon receptor modulator | |
| PH12013502204A1 (en) | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | |
| MX339858B (es) | Compuestos novedosos como ligandos del receptor h3 de la histamina. | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| PH12015500376B1 (en) | Novel bicyclic pyridinones | |
| MX348451B (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12. | |
| MX360330B (es) | Regimen de administracion para nitrocatecoles. | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
| PH12013500545A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| MX2012007783A (es) | Compuestos sulfona que actuan como ligandos del receptor 5-ht6. | |
| MX2013013436A (es) | Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. | |
| EA201390327A1 (ru) | Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов | |
| EA201590413A1 (ru) | Соединения акриламида в качестве лигандов h-рецептора гистамина | |
| WO2013048949A3 (en) | Selective nr2b antagonists | |
| MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. | |
| PH12012502300A1 (en) | Nicotinic receptor non-competitive antagonists | |
| MX2014000855A (es) | Moduladores receptores de glucagon de quinolinilo. | |
| NZ712369A (en) | 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists | |
| TN2013000441A1 (en) | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | |
| PH12014500934A1 (en) | Nicotinic receptor non-competitive modulators | |
| PH12013501453A1 (en) | Nicotinic receptor non-competitive antagonists | |
| UA108500C2 (ru) | Неконкурентные антагонисты никотиновых рецепторов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |